A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FF 21101 Y-90 (Primary)
Indications Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Chondrosarcoma; Clear cell sarcoma; Colorectal cancer; Duodenal cancer; Fallopian tube cancer; Gastrointestinal cancer; Head and neck cancer; Leiomyosarcoma; Liposarcoma; Lung cancer; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Vulvovaginal cancer
Focus Adverse reactions; First in man
Sponsors FujiFilm Pharmaceuticals USA; Strategia Therapeutics

05 Apr 2022 Status changed from active, no longer recruiting to completed.
25 May 2021 Status changed from recruiting to active, no longer recruiting.
17 Jan 2021 Results (n=31)presented at the 2021 Gastrointestinal Cancers Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com